Imiprothrin 

Imiprothrin is an inducer that induces CYP1A2 and metallothionein 1a, with significant genotoxicity and cytotoxicity. In rat hepatocytes, Imiprothrin initiates detoxification responses by triggering the overexpression of these two genes. Imiprothrin induces chromosomal aberrations and micronucleus formation in rat bone marrow cells, and causes DNA damage in hepatocytes. Imiprothrin triggers oxidative stress in rats, leading to lipid peroxidation, excessive reactive oxygen species production and redox imbalance, which in turn impairs liver and kidney functions and causes tissue damage. Imiprothrin inhibits weight gain in mice, and even causes high mortality in female mice at high doses. However, it shows no carcinogenicity in rat experiments; among relevant indicators, aspartate aminotransferase and total protein are identified as sensitive toxicity biomarkers^[1][2].

Imiprothrin (75-100 μg/mL) induces chromosomal aberrations in Chinese hamster lung cells^[1].
Imiprothrin does not induce mutagenicity in Salmonella or E. coli cells in Ames assays conducted with or without metabolic activation^[2].
Imiprothrin does not induce gene mutations in Chinese hamster cells in an in vitro gene mutation assay^[2].
Imiprothrin induces chromosomal aberrations in Chinese hamster lung cells in vitro in the presence of S9 metabolic activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Imiprothrin (19-75 mg/kg; i.p.; daily; 5 consecutive days) induces dose-dependent subacute toxicity in male Wister rats, including oxidative stress, liver and kidney dysfunction, genotoxicity, histopathological injury, and elevated detoxification gene expression, with the 75 mg/kg dose causing the most severe effects including neurotoxic signs^[1].
Imiprothrin (100-7000 ppm; p.o.; ad libitum; 78 consecutive weeks) shows marginal, non-robust increases in mouse lung tumor incidence only at the 7000 ppm dose, which exceeds the maximum tolerated dose (MTD) and produces significant systemic toxicity, while no significant carcinogenic effects are observed at doses at or below the MTD^[2].
Imiprothrin (50-5000 ppm; p.o.; ad libitum; 104 consecutive weeks) shows no evidence of carcinogenic activity in rats up to the maximum tested dose of 5000 ppm, with only mild, non-carcinogenic systemic toxicity observed at the highest dose^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

318.37

C₁₇H₂₂N₂O₄

72963-72-5

O=C(OCN1C(=O)N(CC#C)CC1=O)C2C(C=C(C)C)C2(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mohafrash SMM, et al. Detoxification gene expression, genotoxicity, and hepatorenal damage induced by subacute exposure to the new pyrethroid, imiprothrin, in rats. Environ Sci Pollut Res Int. Published online February 27, 2021.

  [2]. Yamada T, et al. Toxicological evaluation of carcinogenicity of the pyrethroid imiprothrin in rats and mice. Regul Toxicol Pharmacol. 2019;105:1-14.